Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer

BACKGROUND: Pegfilgrastim is recommended in docetaxel plus ramucirumab (DTX + RAM) therapy for recurrent nonsmall cell lung cancer (NSCLC) because of the associated frequency of febrile neutropenia (FN). However, the FN occurs less frequently when the dose of DTX is reduced because of other adverse...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamai, Kosuke, Miyaka, Shinya, Tada, Shinpei, Fujita, Suguru, Hirakawa, Tetsu, Matsumura, Mirai, Ueno, Sayaka, Tanimoto, Takuya, Ishikawa, Nobuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075288/
https://www.ncbi.nlm.nih.gov/pubmed/36727271
http://dx.doi.org/10.1002/cnr2.1793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075288/
https://www.ncbi.nlm.nih.gov/pubmed/36727271
http://dx.doi.org/10.1002/cnr2.1793

Ejemplares similares